Company intelligence / Profile preview

Prime European Therapeuticals

Lodi, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

Prime European Therapeuticals S.p.A. (also known as Euticals) was a privately held Italian company specializing in custom synthesis and manufacturing of active pharmaceutical ingredients (APIs). It was acquired by AMRI (now Curia Global) on July 11, 2016, for approximately $358 million, enhancing AMRI's API capabilities, particularly in Europe. The company is no longer active as a standalone entity post-acquisition.

Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Prime European Therapeuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prime European Therapeuticals.

Explore the full profile